Women in Cardiovascular Clinical Trials: Why Underrepresentation Undermines Cardiovascular Disease Prevention and Treatment
Current Cardiovascular Risk Reports · 12.11.2026 · 20 (1)
DOI: 10.1007/s12170-026-00799-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Cardiovascular Risk Reports, online erschienen am 12.11.2026. Verfasst von Kardie Tobb und 9 weiteren Autor:innen. Die Arbeit nennt 121 Literaturangaben.
Abstract (Originalsprache)
Purpose of the Review This review examines the causes and consequences of women’s underrepresentation in cardiovascular trials and outlines practical strategies to improve trial design, recruitment and reporting. Recent Findings Cardiovascular disease (CVD) is the leading cause of death among women, yet women remain underrepresented in cardiovascular clinical trials. Despite regulatory reforms, enrollment of women in many cardiovascular subspecialty trials remains disproportionately low relative to disease burden. Women also exhibit important differences in cardiovascular risk factors, disease presentation, and treatment response that remain insufficiently studied. This review examines the causes and consequences of women’s underrepresentation in cardiovascular trials and outlines practical strategies to improve trial design, recruitment, and reporting. Summary Historical exclusion has of women created major evidence gaps affecting prevention, diagnosis, pharmacotherapy, device therapy, and guideline development.
Zitieren
APA
Tobb, K., Nasser, S. A., Sharma, G., Bond, R., Islam, S., Sareen, N., Rogers, L., Kharawala, A., Mukunda, N., & Isiadinso, I. (2026). Women in Cardiovascular Clinical Trials: Why Underrepresentation Undermines Cardiovascular Disease Prevention and Treatment. Current Cardiovascular Risk Reports, 20(1). https://doi.org/10.1007/s12170-026-00799-8
Vancouver
Tobb K, Nasser SA, Sharma G, Bond R, Islam S, Sareen N, et al. Women in Cardiovascular Clinical Trials: Why Underrepresentation Undermines Cardiovascular Disease Prevention and Treatment. Current Cardiovascular Risk Reports. 2026;20(1). doi:10.1007/s12170-026-00799-8
BibTeX
@article{Tobb2026,
author = {Tobb, Kardie and Nasser, Samar A. and Sharma, Garima and Bond, Rachel and Islam, Sabrina and Sareen, Nishtha and Rogers, Lanerica and Kharawala, Amrin and Mukunda, Neha and Isiadinso, Ijeoma},
title = {Women in Cardiovascular Clinical Trials: Why Underrepresentation Undermines Cardiovascular Disease Prevention and Treatment},
journal = {Current Cardiovascular Risk Reports},
year = {2026},
volume = {20},
number = {1},
doi = {10.1007/s12170-026-00799-8}
}
EUVIMED